Literature DB >> 12218428

Assessment of symptom exacerbations in a longitudinal study of children with Tourette's syndrome or obsessive-compulsive disorder.

Haiqun Lin1, Chin-Bin Yeh, Bradley S Peterson, Lawrence Scahill, Heidi Grantz, Diane B Findley, Liliya Katsovich, Jessica Otka, Paul J Lombroso, Robert A King, James F Leckman.   

Abstract

OBJECTIVES: The severity of tic and obsessive-compulsive (OC) symptoms varies over time. Consequently, how do we, as clinicians, know when a change in symptom severity occurs that falls outside of the normal range of fluctuation? The goal of this study was to describe the level of symptom severity fluctuation over time and to establish an objective, prospective, and quantitative method for identifying symptom exacerbations in children with Tourette's syndrome, obsessive-compulsive disorder (OCD), or both. A second major aim was to assess whether fluctuations in tic and OC symptom severity covaried with one another.
METHOD: Monthly consecutive Yale Global Tic Severity Scale and Children's Yale-Brown Obsessive Compulsive Scale scores were prospectively obtained in 64 children diagnosed with Tourette's syndrome and/or OCD for periods ranging from 3 to 39 months. Exacerbation thresholds were estimated by using state-of-the-art bootstrap methods. These thresholds were then independently evaluated by asking two expert clinicians to identify, retrospectively, clinically significant exacerbations based on a review of all available clinical and research records.
RESULTS: The severity of tic and OC symptoms displayed a high degree of intrasubject variability. Exacerbation thresholds, which incorporated the change score from the previous month and the current symptom score, provided the best agreement with those of expert clinicians. When both tic and OC symptoms were present, they showed a significant degree of covariation.
CONCLUSIONS: Evidence-based treatments are coming of age. The use of valid, clinician-rated severity scales will likely become a standard part of clinical practice. Bootstrapping methods may provide a quantitative and convenient way to obtain clinically valid thresholds to assess tic and OC symptom exacerbations. This method has the potential to be applied to other symptom domains where exacerbation thresholds are needed.

Entities:  

Mesh:

Year:  2002        PMID: 12218428     DOI: 10.1097/00004583-200209000-00007

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  30 in total

1.  Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism.

Authors:  Thomas V Fernandez; Stephan J Sanders; Ilana R Yurkiewicz; A Gulhan Ercan-Sencicek; Young-Shin Kim; Daniel O Fishman; Melanie J Raubeson; Youeun Song; Katsuhito Yasuno; Winson S C Ho; Kaya Bilguvar; Joseph Glessner; Su Hee Chu; James F Leckman; Robert A King; Donald L Gilbert; Gary A Heiman; Jay A Tischfield; Pieter J Hoekstra; Bernie Devlin; Hakon Hakonarson; Shrikant M Mane; Murat Günel; Matthew W State
Journal:  Biol Psychiatry       Date:  2011-12-14       Impact factor: 13.382

2.  Reactivity of tic observation procedures to situation and setting.

Authors:  John Piacentini; Michael B Himle; Susanna Chang; David E Baruch; Brian A Buzzella; Amanda Pearlman; Douglas W Woods
Journal:  J Abnorm Child Psychol       Date:  2006-10

3.  A cluster analysis of tic symptoms in children and adults with Tourette syndrome: clinical correlates and treatment outcome.

Authors:  Joseph F McGuire; Epiphanie Nyirabahizi; Katharina Kircanski; John Piacentini; Alan L Peterson; Douglas W Woods; Sabine Wilhelm; John T Walkup; Lawrence Scahill
Journal:  Psychiatry Res       Date:  2013-09-27       Impact factor: 3.222

4.  An initial study of family accommodation in children and adolescents with chronic tic disorders.

Authors:  Eric A Storch; Carly Johnco; Joseph F McGuire; Monica S Wu; Nicole M McBride; Adam B Lewin; Tanya K Murphy
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-06-08       Impact factor: 4.785

Review 5.  Systematic review of severity scales and screening instruments for tics: Critique and recommendations.

Authors:  Davide Martino; Tamara M Pringsheim; Andrea E Cavanna; Carlo Colosimo; Andreas Hartmann; James F Leckman; Sheng Luo; Alexander Munchau; Christopher G Goetz; Glenn T Stebbins; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2017-01-10       Impact factor: 10.338

Review 6.  Obsessive-compulsive and tic-related disorders.

Authors:  Martin E Franklin; Julie P Harrison; Kristin L Benavides
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2012-06-16

7.  Identification of pyruvate kinase as an antigen associated with Tourette syndrome.

Authors:  Janice W Kansy; Liliya Katsovich; Kevin S McIver; Jennifer Pick; John B Zabriskie; Paul J Lombroso; James F Leckman; James A Bibb
Journal:  J Neuroimmunol       Date:  2006-10-02       Impact factor: 3.478

8.  Randomized Sham Controlled Double-blind Trial of Repetitive Transcranial Magnetic Stimulation for Adults With Severe Tourette Syndrome.

Authors:  Angeli Landeros-Weisenberger; Antonio Mantovani; Maria G Motlagh; Pedro Gomes de Alvarenga; Liliya Katsovich; James F Leckman; Sarah H Lisanby
Journal:  Brain Stimul       Date:  2014-12-03       Impact factor: 8.955

9.  Tourette syndrome and other tic disorders in childhood, adolescence and adulthood.

Authors:  Andrea G Ludolph; Veit Roessner; Alexander Münchau; Kirsten Müller-Vahl
Journal:  Dtsch Arztebl Int       Date:  2012-11-30       Impact factor: 5.594

10.  Streptococcal upper respiratory tract infections and psychosocial stress predict future tic and obsessive-compulsive symptom severity in children and adolescents with Tourette syndrome and obsessive-compulsive disorder.

Authors:  Haiqun Lin; Kyle A Williams; Liliya Katsovich; Diane B Findley; Heidi Grantz; Paul J Lombroso; Robert A King; Debra E Bessen; Dwight Johnson; Edward L Kaplan; Angeli Landeros-Weisenberger; Heping Zhang; James F Leckman
Journal:  Biol Psychiatry       Date:  2009-10-14       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.